FDA fast-track designation goes to Alkermes' depression candidate

10/11/2013 | American City Business Journals · Bloomberg Businessweek

The FDA has given its fast-track designation to Alkermes' ALKS 5461, an experimental drug for major depressive disorder intended to help patients when other treatments don't provide relief. Alkermes plans to initiate a late-stage trial in early 2014.

View Full Article in:

American City Business Journals · Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA